Shenzhen Edge Medical Co., Ltd. completed an on-market repurchase of 131,500 H-shares on 21 October 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.
The shares were repurchased at prices ranging from HK$31.04 to HK$32.38, representing a volume-weighted average cost of HK$31.94 per share and an aggregate consideration of HK$4.20 million. The transaction was conducted under the general mandate approved by shareholders on 25 June 2026.
Following the buyback, the number of issued shares (excluding treasury shares) fell from 324.31 million to 324.18 million, while treasury shares rose to 3.59 million. The company’s total issued share capital remains unchanged at 327.76 million shares because the repurchased shares are being held in treasury and have not been cancelled.
Since activation of the current mandate, Edge Medical has repurchased 1.97 million shares, equivalent to 0.60% of the issued share base on the mandate date. The company is authorised to repurchase up to 32.61 million shares in total.
Under Hong Kong listing rules, a moratorium on new share issues or sales of treasury shares is in effect until 20 November 2026.
Comments